Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment - 15/05/20
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Funding sources: None. |
|
Conflicts of interest: Dr Gisondi served as consultant for AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Pierre Fabre, Sanofi, and UCB. Dr Girolomoni served as consultant for AbbVie, Abiogen, Almirall, Amgen, Bayer, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Hospira, LEO Pharma, Merck, MSD, Mundipharma, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Sanofi, and Sun Pharma. Drs Del Giglio, Rossi, Zaza, and Iacono have no conflicts of interest to declare. |
|
IRB approval status: The IRB was notified of the observational study. |
|
Reprints not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.